Supplementary Materials

Supplementary Material for:

Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype–positive rheumatoid arthritis patients

Helen Benham, Hendrik J. Nel, Soi Cheng Law, Ahmed M. Mehdi, Shayna Street, Nishta Ramnoruth, Helen Pahau, Bernett T. Lee, Jennifer Ng, Marion E. G. Brunck, Claire Hyde, Leendert A. Trouw, Nadine L. Dudek, Anthony W. Purcell, Brendan J. O'Sullivan, John E. Connolly, Sanjoy K. Paul, Kim-Anh Lê Cao, Ranjeny Thomas*

*Corresponding author. E-mail: ranjeny.thomas{at}uq.edu.au

Published 3 June 2015, Sci. Transl. Med. 7, 290ra87 (2015)
DOI: 10.1126/scitranslmed.aaa9301

This PDF file includes:

  • Fig. S1. Flowchart of the study.
  • Fig. S2. Gating strategy for CD4+ Teff and Treg cells.
  • Fig. S3. Gating strategy for B cell/T cell/Tfh and NKT/DC/monocyte/NK panels shown in table S3.
  • Fig. S4. Effects of Rheumavax on disease activity, Teff and Treg cells, tetanus toxoid immunity, and anti-CCP titer in each treated patient.
  • Fig. S5. Proportion of each group with citrullinated peptide–specific ACPA for the duration of the study.
  • Fig. S6. Ratio of HLA-DR and CD40 expression by modified DC relative to DC before administration.
  • Fig. S7. Frequency of anchor residues from naturally eluted peptides from HLADRB1* 01:01, DRB1*04:01, and DRB1*04:04.
  • Fig. S8. Generation of monocyte-derived DCs from RA PB in the presence of increasing concentrations of Bay11-7082 reduces HLA-DR expression and the capacity to stimulate allogeneic T cells.
  • Table S1. Characteristics, clinical outcomes, and treatment side effects for the 18 study subjects.
  • Table S2. Rheumavax safety toxicity criteria.
  • Table S3. Flow cytometry panels used in the analysis of PBMCs.
  • Table S4. Peptides used in this study.
  • Table S5. Serum analytes measured in this study.
  • Table S6. LME model of serum analytes.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Source data (excel file)

[Download Source Data File]